Ashraf S. Ibrahim, PhD, outlines safety studies and the potential of this antibody therapy for treating this rare fungal infection, which is seemingly becoming less rare.
Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.
A study of carbapenemase-producing organisms found similar rates of infections, highlighting treatment challenges, the role of rapid diagnostics, and surveillance on antimicrobial stewardship due to high mortality rates.
This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.
The need for safe and effective treatment against the various strains of COVID-19 increase, and investigators continue to assess various pharmacologic options.
There has been an emergence of extracorporeal membrane oxygenation-associated infections. Here is a review of how to define them and clinical management of this heterogeneous syndrome.
The healthcare sector currently faces an unmet need in treating herpesviruses, hepatitis B, and hepatitis D, which could significantly improve patient outcomes. Addressing this involves considering the necessary steps and understanding the challenges pharmaceutical companies encounter as they work towards developing treatments for these conditions.
This common skin and soft tissue infection has a high recurrence rate and significant treatment failure. β-Lactams remain effective first-line treatments, though rising resistance to clindamycin and tetracycline, especially in GAS, is a growing concern.
Ken Duncan, PhD, discussed the launch of a $50 million initiative focused on developing new drugs for critical pathogens contributing to antimicrobial resistance.
Clinical and public health laboratories reported increased influenza virus detections over the past few weeks, but US cases remains comparatively low to previous flu seasons.
Deborah Birx, MD, and Amy Carenza, BBA, highlight the targeting of multidrug-resistant organisms and tracking of infection trends without increasing staffing needs.
NACCHO’s CEO Lori Tremmel Freeman discusses efforts and emphasizes the need for federal support and coordination.
This study characterized the incidence of serotonin syndrome and identified contributing risk factors with combined medications for opioid use disorder (MOUD) and linezolid use.
Important clinical considerations to know about resistant CMV infections.
The limitation in the number of pediatric-specific guidelines by professional organizations, and results from large randomized clinical trials, may place an additional emphasis on literature evaluation skills for pediatric ASP pharmacists.
By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.
Expanding the differential for diarrhea beyond Clostridium difficile.
A research team from the Netherlands turns to deep sequencing technology to detect hepatitis C virus resistant variants.
A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.
Biofilms are an emerging clinical problem despite the fact that most clinicians don’t even think of biofilms when managing infections.
Men who have sex with men who seek out sexual partners online are more likely to report sexually transmitted infections, including syphilis, gonorrhea, and chlamydia.
Debra Goff, PharmD, discusses her advocacy around this topic and bringing the stewardship message to dentists about how antibiotic prescribing practices have changed and getting them to recalibrate their thinking and actions in their field.
With IV drug use accounting for 60% of new infections, treatment for individuals in this population is necessary to stave off new infections.
This In the Literature piece explores if we can mitigate some of the adverse reactions that are being seen in obese patients who receive vancomycin through AUC-dosing.
Infections transmitted by these bloodsucking species are on the rise worldwide.